Vor's 'shielded' transplant delays relapse in leukemia patients

Plus: Summit's upcoming lung cancer study reveal

September 13, 2024 Check out STAT+

Sponsored By

José A. Alvarado Jr. for STAT STAT+ | A new drug offers a rare option for brain cancer treatment — and inspires hopes for more FDA-approved last month, the drug from Servier is one of the first major brain tumor breakthroughs in decades, say neuro-oncologists. By Andrew Joseph STAT+ | A rare disease program, portrayed as both lifeline and pharma handout, is set to expire Advocates for people with rare diseases say a voucher program has been essential for attracting investment. Others call it a pharma handout. By Jason Mast and John Wilkerson Blood cell counts have unfairly kept Black and Middle Eastern people from clinical trials, study says The study found that many cancer trials failed to account for natural variation in a type of blood cell called neutrophils. By Angus Chen STAT+ | Can iTeos and GSK solve TIGIT's troubles? Today's biotech news roundup includes thoughts on hopes for TIGIT and questions about Summit Therapeutics' ivonescimab data in lung cancer. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser